The Women's Screening and Self-Testing Program (PROMETA) Study
Launched by TULANE UNIVERSITY · Feb 3, 2025
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The PROMETA Study is a clinical trial designed to improve how we screen for and treat cervical cancer related to the Human Papilloma Virus (HPV) in women. The researchers want to see if they can effectively increase the number of women getting screened for cervical cancer while also ensuring that those who test positive receive the treatment they need. This study will focus on women aged 25 to 49 who are visiting clinics for HIV care and treatment, as they are already accessing health services.
To participate in the study, women must be between 25 and 49 years old, not pregnant, and have a cervix. Unfortunately, women who have had a total hysterectomy (surgery to remove the uterus and cervix) or who have physical or mental challenges that make it hard for them to take part will not be eligible. If you join the study, you can expect to undergo screening for cervical cancer and, if needed, follow-up treatment will be provided. The goal is to gather valuable information that can help improve cervical cancer care in Mozambique in the future.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women 25-49 years
- • Accessing HIV care and treatment services
- • Not being pregnant
- • Patients with a cervix
- Exclusion Criteria:
- • Physical or mental impairment that inhibits participation in the study
- • Pregnant women or \<6 weeks post-partum
- • Women who have undergone a total hysterectomy with removal of the cervix
About Tulane University
Tulane University, a prestigious institution located in New Orleans, Louisiana, is dedicated to advancing medical research and improving public health through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, Tulane leverages its extensive resources and expertise in various fields, including tropical medicine, infectious diseases, and population health. The university's commitment to ethical research practices and patient-centered approaches ensures that clinical trials conducted under its auspices not only contribute to scientific knowledge but also prioritize the well-being of participants. As a leader in clinical research, Tulane University aims to translate findings into tangible health solutions that benefit local communities and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Maputo, , Mozambique
Patients applied
Trial Officials
Troy Moon, MD
Principal Investigator
Tulane University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported